Research programme: synthetic cannabinoid therapeutics - Kalytera Therapeutics

Drug Profile

Research programme: synthetic cannabinoid therapeutics - Kalytera Therapeutics

Alternative Names: K-436; K-671; KAL 439; KAL 671; Synthetic fatty acid amide - Kalytera Therapeutics

Latest Information Update: 10 Aug 2016

Price : $50

At a glance

  • Originator Hebrew University of Jerusalem
  • Developer Kalytera Therapeutics; Tel Aviv University
  • Class Cannabinoids; Fatty acids; Small molecules
  • Mechanism of Action Bone development modulators; Bone resorption factor inhibitors; Cannabinoid receptor CB1 antagonists; Osteoclast inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Fracture; Obesity; Osteogenesis imperfecta; Osteoporosis; Prader-Willi syndrome

Most Recent Events

  • 08 Aug 2016 Kalytera Therapeutics and Shaare Zedek Medical Center enter into research agreement to study genetic markers of osteoporosis in Prader-Willi syndrome
  • 25 Jul 2016 Pharmacodynamics data from a preclinlcal study in Prader-Willi syndrome released by Kalytera Therapeutics
  • 02 Jun 2016 Kalytera Therapeutics in-licenses transdermal technology for the delivery of cannabidiol, KAL 436, KAL 439 and KAL 671 from Delivra in countries worldwide, except Canada
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top